Lilly Pulls EU Approval Application For Olumiant In COVID-19

The European Medicines Agency says it does not have enough data to justify the approval of Olumiant for hospitalized COVID-19 patients. The marketing authorization application for another product, Reata’s Imbarkyd for chronic kidney disease, has also been withdrawn.  

Microscopic view of Coronavirus, a pathogen that attacks the respiratory tract. Analysis and test, experimentation. Sars. 3d render
The EMA says it cannot approve Olumiant for COVID-19 at present • Source: Shutterstock

Lilly Nederland BV has withdrawn the EU marketing authorization application (MAA) for its Janus kinase inhibitor, Olumiant (baricitinib), for use in treating adults and children with COVID-19 who require supplemental oxygen, after the European Medicines Agency said the company had not provided enough data for an approval recommendation.

Another product has been also pulled from the EMA review process: Reata Pharmaceuticals, Inc.'s Imbarkyd (bardoxolone methyl), which had...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography